CSL Limited today released its results for the six months to 31 Dec, with the company’s net profit after tax surging 34.9% to a whopping US$1.1 billion.
Revenues from continuing operations rose 12.8% to US$4.1b, with highlights including a 26% increase in revenue for the Seqirus vaccine division, “driven largely by increased sales of seasonal influenza vaccines”.
The Seqirus portfolio is transitioning towards higher-valued quadrivalent products Flucelvax and Afluria, while growth was also driven by a significant increase in sales of Fluad, Seqirus’ adjuvanted influenza vaccine designed to offer increased protection for over 65-year-olds.
The CSL Behring blood products division also performed well with increasing sales of immunoglobulin products underpinned by demand for Privigen and Hizentra.
CSL said its Idelvion haemophilia product sales increased more than threefold over the period.